JAK Inhibitors
Janus Kinases (JAKs) are a family of intracellular non-receptor tyrosine kinases (JAK1, JAK2, JAK3, TYK2) that are indispensable components of cytokine and growth factor signaling pathways. Upon ligand binding to their cognate cell surface receptors, JAKs associated with these receptors undergo activation through trans-phosphorylation. Activated JAKs then phosphorylate specific tyrosine residues on the receptor cytoplasmic tails, creating docking sites for Signal Transducers and Activators of Transcription (STAT) proteins. STATs are subsequently phosphorylated by JAKs, leading to their dimerization, translocation to the nucleus, and binding to specific DNA sequences to regulate gene expression. This JAK-STAT pathway mediates a vast array of cellular processes, including hematopoiesis, immune cell development and function, inflammation, and cell proliferation and survival. Different JAKs are activated by specific cytokine receptors; for instance, JAK1 and JAK3 are crucial for signaling through receptors that share the common gamma chain (e.g., IL-2, IL-7, IL-15), JAK1 and JAK2 are involved in IL-6 and IFN-gamma signaling, while JAK2 is critical for erythropoietin (EPO) and thrombopoietin (TPO) receptor signaling. Aberrant activation of JAKs is implicated in numerous diseases.
JAK inhibitors are a rapidly expanding class of small molecule drugs primarily developed for inflammatory and autoimmune diseases, as well as myeloproliferative neoplasms (MPNs). In autoimmune conditions like rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, Crohn's disease, and atopic dermatitis, overactive cytokine signaling drives chronic inflammation. In MPNs such as myelofibrosis and polycythemia vera, mutations (e.g., JAK2 V617F) lead to constitutive JAK activation, resulting in uncontrolled hematopoiesis. JAK inhibitors are also used in graft-versus-host disease (GvHD). Research into JAK inhibitors has led to the approval of several groundbreaking drugs. Tofacitinib (Xeljanz), a pan-JAK inhibitor with greater selectivity for JAK1 and JAK3, was the first approved for rheumatoid arthritis, later expanding to psoriatic arthritis and ulcerative colitis. Ruxolitinib (Jakafi/Jakavi), a JAK1/2 inhibitor, is approved for myelofibrosis, polycythemia vera, and GvHD.
Baricitinib (Olumiant), another JAK1/2 inhibitor, is approved for RA and atopic dermatitis. More selective JAK1 inhibitors, such as upadacitinib (Rinvoq) and filgotinib (Jyseleca), have since been approved for various inflammatory conditions, aiming for improved safety profiles by minimizing off-target effects. Deucravacitinib (Sotyktu) represents a new generation, being a selective allosteric inhibitor of TYK2, approved for psoriasis. Many other JAK inhibitors with varying selectivity profiles are in late-stage clinical development. JAK inhibitors are classified by their selectivity for specific JAK isoforms: (1) Pan-JAK inhibitors (e.g., tofacitinib, less selective); (2) JAK1/2 inhibitors (e.g., ruxolitinib, baricitinib); (3) selective JAK1 inhibitors (e.g., upadacitinib, filgotinib); (4) selective JAK3 inhibitors (less common due to immunosuppression concerns); and (5) selective TYK2 inhibitors (e.g., deucravacitinib). Key research tool compounds include various small molecule inhibitors targeting specific JAKs. Challenges include dose-dependent side effects such as increased risk of infections (especially herpes zoster), anemia, thrombocytopenia, hyperlipidemia, and venous thromboembolism.
The development of more selective inhibitors aims to mitigate these off-target effects and improve the overall safety profile. Combination therapies are less common than with biologics, but JAK inhibitors are sometimes used with conventional DMARDs or corticosteroids.
